INSPIRA Technologies

Inspira and Qarakal signed a Joint Development Agreement to test and evaluate Inspira’s QTREX AME technology under quantum-relevant cryogenic conditions in a working superconducting quantum environment. Read more >> globenewswire.com/news-relea…

Inspira received a $390,000 payment for an AME system purchase order from a premier APAC university recognized for quantum computing and quantum information networks, establishing recurring revenue from consumables and annual service fees. Read more >> globenewswire.com/news-relea…

Inspira announced the successful delivery and acceptance of its AME system at a Tier-1 U.S. defense customer site under a commercial agreement. The engagement also includes ongoing supply of proprietary consumables and materials. Read more >> globenewswire.com/news-relea…

Inspira Technologies appointed Yoav Rozanovich as Chief Business Officer to drive immediate revenue growth and quantum expansion, reinforcing its commercial execution following the acquisition of the AME business from Nano Dimension. Read more >> finance.yahoo.com/sectors/te…

Inspira begins an AME technology implementation process with a customer that is one of the world’s 10 largest U.S.-based companies, reinforcing recurring revenue-generating activity and supporting its expansion into advanced technology markets. Read more >> finance.yahoo.com/sectors/te…

Inspira enters the quantum computing sector, targeting a critical connectivity bottleneck with its newly acquired AME platform. The Company is targeting a new 3D connectivity architecture for use in dilution cryostats. Read more >> globenewswire.com/news-relea…

Inspira announced the acquisition of Nano Dimension’s AME platform, including IP, customer-related assets and commercial operations, positioning the Company for the next stage of its strategy. Further strategic update to follow shortly. Read more >> globenewswire.com/news-relea…

Inspira Technologies reports full year 2025 financial results and provides business updates, highlighting clinical validation and early commercial traction toward 2026 revenue scale. $IINN Read more >> globenewswire.com/news-relea…

$IINN News: Inspira Expands U.S. Commercial Footprint! Inspira deploys INSPIRA™ ART100 at a premier New York Academic Medical Center, ranked Top 10 in NY State. This expands Inspira’s presence within the Tier-1 U.S. hospital market. Read more >> globenewswire.com/news-relea…

Meet us at AmSECT 2026 (Austin, TX | March 25–29) at the Glo-Med Networks booth. We’ll be there throughout the conference to connect with the perfusion community and share the latest on INSPIRA™ ART100. To set up a quick meeting during AmSECT: Mike Hershkovitz, VP Global Sales [email protected] Read more >> finance.yahoo.com/news/inspi…

Inspira received official approval from Clalit’s Medical Equipment Committee (world’s 2nd largest integrated HMO; $12B revenue), enabling INSPIRA™ ART100 for immediate procurement & operational use across Clalit's extensive medical ecosystem. $IINN Read more >> globenewswire.com/news-relea…

Validated next-gen standalone HYLA™: 94.2% accuracy for blood pCO₂ measurement. Provides continuous, non-invasive visibility. Pivot to standalone targets $48B heart-lung surgery market upon clearance. $IINN globenewswire.com/news-relea…

FDA-cleared INSPIRA™ ART100 has completed a full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center. ~30 patients treated; ART100 systems incorporated into routine workflow. $IINN Read more >> globenewswire.com/news-relea…

$22.5M & $27M binding purchase orders advanced to final budgetary validation & fund allocation within gov’t authorities’ procurement processes. ~91% cleared commercial/admin review, prior to fund release & operational execution, subject to approvals. $IINN globenewswire.com/news-relea…

Operational efficiency starts with smarter design. HYLA™ Blood Monitoring is developed to reduce complexity and cut consumable use, with one universal sensor that fits multiple systems and tubing sizes. No manual sampling. No cuvettes. This means simplified procurement, lower overhead, and streamlined workflows - all without compromising on accuracy. Disclaimer: HYLA™ has not been cleared or approved by the FDA or any other regulatory authority. Availability is subject to future regulatory authorization.

Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion. “The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira”. $IINN Read more >> globenewswire.com/news-relea…

Inspira announced a non-binding term sheet for a proposed acquisition of an advanced liquid biopsy diagnostics business alongside a concurrent $15M strategic equity investment into Inspira at $180M valuation subject to definitive agreements. $IINN Read more >> globenewswire.com/news-relea…

Happy New Year from Inspira Technologies!

Happy Holidays to our global community. Wishing our partners, clinicians, and shareholders a season of light, gratitude, and meaningful progress. Thank you for being part of Inspira’s journey as we continue building and advancing our technology platform. Merry Christmas, and a bright New Year.

In critical care, every second matters - but blood data often arrives too late. HYLA™ blood monitoring is being developed to change that. It’s a smart, non-invasive blood sensor that continuously monitors key parameters in real time - without blood draws, without cuvettes, and without delays. When time is short, HYLA™ blood monitoring aims to deliver immediate answers. * HYLA™ has not been cleared or approved by the FDA or any other regulatory authority.